ListarMD - Artículos por tema "BIOBADALER"
Mostrando ítems 1-1 de 1
-
Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria
Zubiaga- Fernandez, L.; Testera Montes, Almudena; Rondon, C.; Perez-Sanchez, N.; Gomez- Perez, F.; Vega-Chicote, J. M.; Bartra, Joan; Ferrer, M.; Eguiluz-Gracia, Ibón; Torres-Jaén, María Josefa
[et al.] (Wiley, 2024-02-11)
Background Clinical trials showed the efficacy of 300 mg/4 weeks of omalizumab (OMA) during 6 months in patients with severe chronic spontaneous urticaria (CSU). Nevertheless, in real life, many patients require higher ...